Tobacco produces an impressive burden of disease resulting in premature death in half of users. Despite effective smoking cessation medications (nicotine replacement therapies, bupropion and varenicline), there is a very high rate of relapse following quit attempts. The use of efficient strategies for the development of novel treatments is a necessity. A 'bench to bedside strategy' was initially used to develop cannabinoid CB 1 receptor antagonists for the treatment of nicotine addiction. Unfortunately, after being tested on experimental animals, what seemed to be an interesting approach for the treatment of nicotine addiction resulted in serious unwanted side effects when tested in humans. Current research is focusing again on pre-clinical models in an effort to eliminate unwanted side effects while preserving the initially observed efficacy. A 'bed side to bench strategy' was used to study the role of the insula (part of the frontal cortex) in nicotine addiction. This line of research started based on clinical observations that patients suffering stroke-induced lesions to the insula showed a greater likelihood to report immediate smoking cessation without craving or relapse. Subsequently, animal models of addiction are used to explore the role of insula in addiction. Due to the inherent limitations existing in clinical versus preclinical studies, the possibility of close interaction between both models seems to be critical for the successful development of novel therapeutic strategies for nicotine dependence.
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Introduction
Tobacco, one of the most widely used substances, is responsible for 63% of all deaths produced by non-communicable diseases and resulting in nearly six million deaths each year, a figure expected to rise to more than eight million by 2030 (WHO, 2013 . The devastating effects of tobacco are also suffered by people dying as a result of exposure to second-hand smoke, accounting for more than 600,000 deaths each year. Nicotine is the main component of tobacco responsible for its addictive properties and extensive research has been and is currently being conducted to elucidate the neurobiological mechanisms responsible for its addictive properties. However, improved research strategies are critical in view of the overwhelming increase in the death toll related to tobacco use predicted. It is also important to consider that approximately 80% of smokers worldwide are located in low/middle income countries (WHO, 2013) , which makes the development of low cost treatments a necessity. Current first line medications for nicotine dependence include nicotine replacement Abbreviations: α4β2, ALPHA-4 beta-2 nicotinic receptor; β2, nicotinic receptor subunit; AM251, inverse agonist at the CB 1 cannabinoid receptor; AM4113, CB 1 putative neutral antagonist; BOLD, blood-oxygen-level dependent; cAMP, Cyclic Adenosine Monophosphate; CB 1 , cannabinoid receptor type 1; CB 2 , cannabinoid receptor type 2; CPP, conditioned place preference; DBS, deep brain stimulation; EU, European Union; FDA, Food and Drug Administration; fMRI, functional magnetic resonance imaging; GABA, gamma-aminobutyric acid; GABAb, metabotropic transmembrane receptor for gamma-aminobutyric acid; Hypocretin-1, orexin-A; kDa, kiloDalton; K i , inhibition constant; nAChRs, nicotinic receptors; nM, nanomolar; Rimonabant, inverse agonist at the CB 1 cannabinoid receptor; rTMS, transcranial magnetic stimulation; SCH23390, D1 receptor antagonist; 
